| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
|---|
Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
|---|---|---|---|---|---|---|---|---|
| Q4 2024 | 39 | $7.07B | +$538M | -$168M | +$370M | UTHR, ARGX, ASND, MDGL, KRYS | 13F-HR | 2/14/2025, 08:34 AM |
| Q3 2024 | 35 | $6.86B | +$301M | -$1.13B | -$827M | UTHR, ASND, ARGX, KRYS, MDGL | 13F-HR | 11/14/2024, 07:59 AM |
| Q2 2024 | 41 | $7.51B | +$255M | -$1.18B | -$924M | UTHR, MDGL, ASND, ARGX, SRPT | 13F-HR | 8/14/2024, 07:58 AM |
| Q1 2024 | 46 | $8.57B | +$1.7B | -$873M | +$830M | UTHR, APLS, ASND, SRPT, MDGL | 13F-HR | 5/15/2024, 08:07 AM |
| Q4 2023 | 42 | $7.24B | +$1.5B | -$1.48B | +$16.3M | APLS, UTHR, ASND, ARGX, MDGL | 13F-HR | 2/14/2024, 12:05 PM |
| Q3 2023 | 45 | $6.41B | +$266M | -$764M | -$498M | HZNP, UTHR, ARGX, SRPT, APLS | 13F-HR | 11/14/2023, 06:32 AM |
| Q2 2023 | 43 | $7.37B | +$486M | -$166M | +$320M | APLS, HZNP, UTHR, SRPT, ARGX | 13F-HR | 8/14/2023, 07:33 AM |
| Q1 2023 | 38 | $6.74B | +$304M | -$21.4M | +$283M | HZNP, APLS, UTHR, SRPT, ARGX | 13F-HR | 5/15/2023, 09:09 AM |
| Q4 2022 | 36 | $6.69B | +$473M | -$55.7M | +$417M | UTHR, HZNP, APLS, MDGL, ARGX | 13F-HR | 2/14/2023, 09:04 AM |
| Q3 2022 | 39 | $5.41B | +$264M | -$196M | +$68.8M | APLS, UTHR, ARGX, MRTX, SRPT | 13F-HR | 11/14/2022, 09:28 AM |
| Q2 2022 | 40 | $5.06B | +$322M | -$395M | -$73M | UTHR, ARGX, APLS, HZNP, MRTX | 13F-HR | 8/15/2022, 08:54 AM |
| Q1 2022 | 43 | $5.48B | +$789M | -$411M | +$377M | HZNP, UTHR, APLS, MRTX, ARGX | 13F-HR | 5/16/2022, 08:57 AM |
| Q4 2021 | 40 | $5.86B | +$640M | -$1.23B | -$589M | HZNP, MRTX, UTHR, APLS, ARGX | 13F-HR | 2/14/2022, 09:03 AM |
| Q3 2021 | 43 | $6.34B | +$603M | -$364M | +$239M | HZNP, MRTX, XLRN, UTHR, ASND | 13F-HR | 11/15/2021, 09:04 AM |
| Q2 2021 | 44 | $5.74B | +$644M | -$498M | +$147M | HZNP, MRTX, UTHR, XLRN, ARGX | 13F-HR | 8/16/2021, 09:05 AM |
| Q1 2021 | 46 | $5.79B | +$1.09B | -$373M | +$721M | HZNP, MRTX, UTHR, XLRN, VRTX | 13F-HR | 5/17/2021, 09:29 AM |
| Q4 2020 | 43 | $5.81B | +$1.14B | -$3.07B | -$1.93B | MRTX, HZNP, UTHR, IOVA, ARNA | 13F-HR | 2/16/2021, 12:33 PM |
| Q3 2020 | 46 | $7.04B | +$727M | -$353M | +$374M | IMMU, MRTX, HZNP, IOVA, ASND | 13F-HR | 11/16/2020, 09:02 AM |
| Q2 2020 | 44 | $5.06B | +$743M | -$193M | +$550M | IMMU, MRTX, HZNP, IOVA, SRPT | 13F-HR | 8/14/2020, 10:00 AM |
| Q1 2020 | 41 | $2.96B | +$489M | -$50.7M | +$439M | IMMU, MRTX, IOVA, ASND, BMRN | 13F-HR | 5/15/2020, 01:03 PM |
| Q4 2019 | 29 | $3.4B | +$494M | -$515M | -$20.6M | IMMU, MRTX, ASND, IOVA, SRPT | 13F-HR | 2/14/2020, 09:47 AM |
| Q3 2019 | 33 | $2.4B | +$220M | -$168M | +$51.9M | MRTX, IMMU, IOVA, ASND, BMRN | 13F-HR | 11/14/2019, 12:40 PM |
| Q2 2019 | 33 | $2.89B | +$531M | -$176M | +$354M | MRTX, IMMU, IOVA, ASND, SRPT | 13F-HR | 8/14/2019, 12:04 PM |
| Q1 2019 | 31 | $2.31B | +$299M | -$249M | +$50.2M | IMMU, MRTX, ASND, AMRN, SRPT | 13F-HR | 5/15/2019, 12:26 PM |
| Q4 2018 | 33 | $1.67B | +$198M | -$306M | -$107M | IMMU, MRTX, SRPT, ASND, BMRN | 13F-HR | 2/14/2019, 11:11 AM |
| Q3 2018 | 43 | $2.18B | +$170M | -$536M | -$366M | IMMU, MRTX, SRPT, ASND, BMRN | 13F-HR | 11/14/2018, 11:16 AM |
| Q2 2018 | 41 | $2.59B | +$690M | -$444M | +$246M | IMMU, MRTX, BMRN, FOLD, ASND | 13F-HR | 8/14/2018, 11:25 AM |
| Q1 2018 | 50 | $2.09B | +$561M | -$148M | +$413M | IMMU, FOLD, BMRN, IOVA, MRTX | 13F-HR | 5/15/2018, 12:51 PM |
| Q4 2017 | 44 | $1.53B | +$360M | -$171M | +$190M | IMMU, BMRN, FOLD, MRTX, CLVSQ | 13F-HR | 2/14/2018, 11:43 AM |
| Q3 2017 | 39 | $1.27B | +$446M | -$152M | +$293M | IMMU, FOLD, KITE, ARRY, CLVSQ | 13F-HR | 11/14/2017, 12:23 PM |
| Q2 2017 | 42 | $789M | +$188M | -$197M | -$9.52M | IMMU, KITE, FOLD, TSRO, BMRN | 13F-HR | 8/14/2017, 12:30 PM |
| Q1 2017 | 42 | $782M | +$310M | -$127M | +$183M | IMMU, TSRO, MDCO, ACAD, BMRN | 13F-HR | 5/15/2017, 12:20 PM |
| Q4 2016 | 39 | $494M | +$101M | -$81M | +$19.6M | ACAD, IMMU, BMRN, LBIO, TSRO | 13F-HR | 2/14/2017, 12:27 PM |
| Q3 2016 | 44 | $563M | +$109M | -$116M | -$7.06M | SRPT, BMRN, LBIO, TSRO, FOLD | 13F-HR | 11/14/2016, 03:38 PM |
| Q2 2016 | 38 | $445M | +$184M | -$41.2M | +$143M | TSRO, LBIO, CPXX, BMRN, BMY | 13F-HR | 8/15/2016, 04:09 PM |
| Q1 2016 | 33 | $284M | +$129M | -$52.2M | +$76.5M | MRTX, FOLD, BMRN, SRPT, GILD | 13F-HR | 5/16/2016, 04:06 PM |
| Q4 2015 | 28 | $290M | +$23.4M | -$92.2M | -$68.8M | MRTX, FOLD, LBIO, LJPC, SRPT | 13F-HR | 2/12/2016, 12:00 PM |
| Q3 2015 | 29 | $378M | +$124M | -$43.9M | +$79.8M | FOLD, MRTX, VNDA, LJPC, ACAD | 13F-HR | 11/13/2015, 12:27 PM |
| Q2 2015 | 30 | $362M | +$142M | -$77.5M | +$64.2M | FOLD, SRNE, MRTX, LBIO, ONTY | 13F-HR | 8/14/2015, 12:31 PM |
| Q1 2015 | 33 | $261M | +$138M | -$39.4M | +$98.2M | FOLD, LBIO, SRNE, PTX, BLCM | 13F-HR | 5/15/2015, 11:59 AM |
| Q4 2014 | 27 | $144M | $0 | $0 | FOLD, TARO, RCPT, PTX, AGEN | 13F-HR | 2/13/2015, 01:07 PM |